[Bio Story] First Decision in Alteogen-Halozyme Dispute Set for Early Next Month
Taeyeon Jeon, CEO of Alteogen, Interview ②
"Halozyme's Claims Violate Fundamental Principles of Patent Law"
"Even in the Worst Case, We Can Fight Again"
Taeyeon Jeon, CEO of Alteogen, stated during an interview with The Asia Business Daily at the company's headquarters in Yuseong-gu, Daejeon on April 23 that, regarding the ongoing patent dispute initiated by Halozyme in the United States against Alteogen, "So far, it is proceeding very favorably." Alteogen supplies its core enzyme, ALT-B4, which converts intravenous (IV) drugs into subcutaneous (SC) injections, to global pharmaceutical giants such as Merck (MSD). Halozyme, the leading company in this same market, has taken action by claiming that Alteogen has infringed on its patent. Out of several ongoing disputes, the first decision is set to be delivered in early June.
The disputes surrounding Alteogen are divided into three branches: a patent invalidation trial filed by Merck against Halozyme; another patent invalidation trial filed by Halozyme against Alteogen; and a patent infringement lawsuit filed by Halozyme against Merck at the U.S. District Court in New Jersey.
The first result to be announced will be the invalidation trial (PGR) that Merck filed with the U.S. Patent Trial and Appeal Board (PTAB). Merck is seeking to invalidate a patent on a modified hyaluronidase enzyme (MDASE) held by Halozyme. Hyaluronidase is an enzyme that helps drugs spread more easily under the skin when converting from IV to SC injection. Both Alteogen's ALT-B4 and Halozyme's proprietary enzyme belong to this class. If Halozyme is granted broad rights under this patent, it could restrict the development of follow-up products, including Keytruda SC, which Merck has launched in partnership with Alteogen. This is the reason Merck has directly initiated the invalidation proceedings.
Merck put forth two main arguments for invalidation. First, Halozyme is claiming rights not only over substances it has actually created and verified, but also over a vast number of theoretically possible modified enzymes. CEO Jeon described it as "the number of variants Halozyme claims is greater than all the grains of sand on Earth."
He also argued that such broad claims are inconsistent with the fundamental principles of patent law. To be granted a patent, the invention must be reproducible by other researchers based solely on the patent documents. Claiming exclusive rights to areas that have never actually been made or tested violates this principle.
Previously, Halozyme made two attempts to block this trial from proceeding. One was to petition the Director of the U.S. Patent and Trademark Office to dismiss the case at their discretion. The other was to challenge the eligibility of Merck's representatives by alleging improper involvement in the process. Both were rejected. The U.S. Patent Trial and Appeal Board's final decision on the validity of Halozyme's MDASE patent is scheduled for early June.
Taeyeon Jeon, CEO of Alteogen, held an interview with The Asia Business Daily at the company's headquarters in Yuseong-gu, Daejeon on the 23rd of last month. Regarding the patent dispute initiated by Halozyme in the United States against the company, he stated, "So far, it is proceeding very favorably." Photo by Donghun Jung
View original imageCEO Jeon cautioned against interpreting the outcome of this trial as being directly linked to Alteogen's business trajectory. Merck's PGR is a procedure solely to determine the validity of Halozyme's patent itself; it does not address whether Alteogen's ALT-B4 infringes upon that patent. Even if Halozyme prevails in the PGR and the patent survives, it does not automatically mean that ALT-B4 is infringing upon it.
Furthermore, Alteogen maintains that ALT-B4 itself lies outside the scope of Halozyme's patent rights. ALT-B4 is a unique variant with a structure different from the natural enzyme, and according to CEO Jeon, it operates via a mechanism different from what Halozyme's patent claims. In other words, ALT-B4 is a unique variant with a structure different from the natural enzyme and operates via a mechanism distinct from what is claimed by the Halozyme patent.
CEO Jeon said, "We have already obtained freedom-to-operate (FTO) opinions from top intellectual property law firms in the United States, stating that ALT-B4 does not infringe on Halozyme's patent. In addition, all eight global partner companies, including Merck, conducted their own patent due diligence prior to signing contracts, and all passed. The fact that these major pharmaceutical companies have directly verified and contracted with us is the strongest evidence."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Alteogen is also responding through local U.S. law firms to another invalidation trial (IPR) separately initiated by Halozyme targeting its manufacturing process patents. The contract with Merck clearly stipulates that, regardless of the outcome of any dispute, the royalties to be received by Alteogen will remain unchanged. CEO Jeon added, "Recently, even among our potential global partners in negotiations, there is a growing consensus that Halozyme's patent will likely be invalidated. In fact, the number of patent-related questions in new contract negotiations has noticeably decreased."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.